title: Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Sashegyi
authors.forename: Yong
authors.initials: Y
authors.lastname: Lin
authors.forename: David
authors.initials: D
authors.lastname: Ferry
authors.forename: Allen
authors.initials: A
authors.lastname: Melemed
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000453:epidemiology*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal